Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Calcitriol
Form:
11 of 11 products shown
8 general benefit · 1 Limited Use · 2 not a benefit
Calcitriol-Odan · DIN 02431637 · 0.25 mcg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Calcitriol-Odan · DIN 02431637
Manufacturer: Odan Laboratories Ltd.; listing date 2016-03-30
Health Canada: Marketed since 2014-10-10 · brand CALCITRIOL-ODAN · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.25 MCG · company Odan laboratoriesltd · schedule Prescription
Calcitriol-Odan: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2341). What the ministry pays, not the patient.
DIN 02431637: Calcitriol-Odan
Raw flags: sec3=Y
Item: 881600005; group id 886; item number 2130; lccId None; manufacturer id ODN
Source form: Cap; strength: 0.25mcg
Recorded listing: General benefit
Source prices (unrounded): $0.2341; ministry $0.2341
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02431637
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91612Interchangeable products
PMS-Calcitriol · DIN 02495899 · $0.2341
Rocaltrol · DIN 00481823 · $0.2341
Taro-Calcitriol · DIN 02485710 · $0.2341
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02431637
Shortage record checked October 6, 2026
Rocaltrol · DIN 00481823 · 0.25 mcg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists Rocaltrol (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists Rocaltrol (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, September 10, 2026 ↗)
1 brand, same coverage
Rocaltrol · DIN 00481823
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Health Canada: Marketed since 2022-03-14 · brand ROCALTROL · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.25 MCG · company Searchlight pharma inc · schedule Prescription
DIN 00481823: Rocaltrol
Raw flags: sec3=Y
Item: 881600005; group id 886; item number 2130; lccId None; manufacturer id HLR
Source form: Cap; strength: 0.25mcg
Recorded listing: General benefit
Source prices (unrounded): $0.7071; ministry $0.2341
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00481823
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3430Interchangeable products
Calcitriol-Odan · DIN 02431637 · $0.2341
PMS-Calcitriol · DIN 02495899 · $0.2341
Taro-Calcitriol · DIN 02485710 · $0.2341
Shortage status: resolved shortage (ended December 8, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00481823
Shortage record checked October 6, 2026
Taro-Calcitriol · DIN 02485710 · 0.25 mcg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Calcitriol · DIN 02485710
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2019-12-20
Health Canada: Marketed since 2019-06-03 · brand TARO-CALCITRIOL · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.25 MCG · company Taro pharmaceuticals inc · schedule Prescription
Taro-Calcitriol: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2341). What the ministry pays, not the patient.
DIN 02485710: Taro-Calcitriol
Raw flags: sec3=Y
Item: 881600005; group id 886; item number 2130; lccId None; manufacturer id TAR
Source form: Cap; strength: 0.25mcg
Recorded listing: General benefit
Source prices (unrounded): $0.2341; ministry $0.2341
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485710
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97594Interchangeable products
Calcitriol-Odan · DIN 02431637 · $0.2341
PMS-Calcitriol · DIN 02495899 · $0.2341
Rocaltrol · DIN 00481823 · $0.2341
Shortage status: resolved shortage (ended December 9, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485710
Shortage record checked October 6, 2026
Calcitriol-Odan · DIN 02431645 · 0.5 mcg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Calcitriol-Odan · DIN 02431645
Manufacturer: Odan Laboratories Ltd.; listing date 2016-06-29
Health Canada: Marketed since 2014-10-10 · brand CALCITRIOL-ODAN · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.5 MCG · company Odan laboratoriesltd · schedule Prescription
Calcitriol-Odan: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3723). What the ministry pays, not the patient.
DIN 02431645: Calcitriol-Odan
Raw flags: sec3=Y
Item: 881600004; group id 886; item number 2131; lccId None; manufacturer id ODN
Source form: Cap; strength: 0.5mcg
Recorded listing: General benefit
Source prices (unrounded): $0.3723; ministry $0.3723
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02431645
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91613Interchangeable products
PMS-Calcitriol · DIN 02495902 · $0.3723
Rocaltrol · DIN 00481815 · $0.3723
Taro-Calcitriol · DIN 02485729 · $0.3723
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02431645
Shortage record checked October 6, 2026
Rocaltrol · DIN 00481815 · 0.5 mcg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists Rocaltrol (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists Rocaltrol (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, September 10, 2026 ↗)
1 brand, same coverage
Rocaltrol · DIN 00481815
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Health Canada: Marketed since 2022-03-14 · brand ROCALTROL · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.5 MCG · company Searchlight pharma inc · schedule Prescription
DIN 00481815: Rocaltrol
Raw flags: sec3=Y
Item: 881600004; group id 886; item number 2131; lccId None; manufacturer id HLR
Source form: Cap; strength: 0.5mcg
Recorded listing: General benefit
Source prices (unrounded): $1.1246; ministry $0.3723
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00481815
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3429Interchangeable products
Calcitriol-Odan · DIN 02431645 · $0.3723
PMS-Calcitriol · DIN 02495902 · $0.3723
Taro-Calcitriol · DIN 02485729 · $0.3723
Shortage status: resolved shortage (ended December 10, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00481815
Shortage record checked October 6, 2026
Taro-Calcitriol · DIN 02485729 · 0.5 mcg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Calcitriol · DIN 02485729
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2019-12-20
Health Canada: Marketed since 2019-06-03 · brand TARO-CALCITRIOL · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.5 MCG · company Taro pharmaceuticals inc · schedule Prescription
Taro-Calcitriol: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3723). What the ministry pays, not the patient.
DIN 02485729: Taro-Calcitriol
Raw flags: sec3=Y
Item: 881600004; group id 886; item number 2131; lccId None; manufacturer id TAR
Source form: Cap; strength: 0.5mcg
Recorded listing: General benefit
Source prices (unrounded): $0.3723; ministry $0.3723
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485729
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97595Interchangeable products
Calcitriol-Odan · DIN 02431645 · $0.3723
PMS-Calcitriol · DIN 02495902 · $0.3723
Rocaltrol · DIN 00481815 · $0.3723
Shortage status: resolved shortage (ended January 18, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485729
Shortage record checked October 6, 2026
PMS-Calcitriol · DIN 02495899 · 0.25 mcg · capsule
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Calcitriol · DIN 02495899
Manufacturer: Pharmascience Inc.; listing date 2020-11-30
Health Canada: Dormant since 2024-07-31 · brand PMS-CALCITRIOL · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.25 MCG · company Pharmascience inc · schedule Prescription
PMS-Calcitriol: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2341). What the ministry pays, not the patient.
DIN 02495899: PMS-Calcitriol
Raw flags: sec3=Y
Item: 881600005; group id 886; item number 2130; lccId None; manufacturer id PMS
Source form: Cap; strength: 0.25mcg
Recorded listing: General benefit
Source prices (unrounded): $0.2341; ministry $0.2341
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02495899
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98579Interchangeable products
Calcitriol-Odan · DIN 02431637 · $0.2341
Rocaltrol · DIN 00481823 · $0.2341
Taro-Calcitriol · DIN 02485710 · $0.2341
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495899
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2024 — choose a marketed DIN from the same-category list.
PMS-Calcitriol · DIN 02495902 · 0.5 mcg · capsule
General benefitDormant since July 31, 2024 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Calcitriol · DIN 02495902
Manufacturer: Pharmascience Inc.; listing date 2020-11-30
Health Canada: Dormant since 2024-07-31 · brand PMS-CALCITRIOL · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.5 MCG · company Pharmascience inc · schedule Prescription
PMS-Calcitriol: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3723). What the ministry pays, not the patient.
DIN 02495902: PMS-Calcitriol
Raw flags: sec3=Y
Item: 881600004; group id 886; item number 2131; lccId None; manufacturer id PMS
Source form: Cap; strength: 0.5mcg
Recorded listing: General benefit
Source prices (unrounded): $0.3723; ministry $0.3723
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02495902
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98580Interchangeable products
Calcitriol-Odan · DIN 02431645 · $0.3723
Rocaltrol · DIN 00481815 · $0.3723
Taro-Calcitriol · DIN 02485729 · $0.3723
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495902
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2024 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefitDormant since April 23, 2025 · checked November 16, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Sterimax Calcitriol Injection; DOSAGE FORM/ STRENGTH: 1 mcg/mL — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Calcitriol
Brand(s): Sterimax Calcitriol Injection
DOSAGE FORM/ STRENGTH: 1 mcg/mL
Case-by-case funding is provided for dialysis patients. Please submit all relevant
clinical data to enable an assessment by the EAP.
Calcitriol Injection, USP (calcitriol) 1mcg/mL Inj Sol – 1mL Pk (imported by STE) –
Effective Date: July 17, 2024
This imported US product (PIN 09858344) is funded under the EAP on a temporary
basis case by case and for those stabilized with an existing EAP approval. This is to
manage a product shortage of calcitriol injection 1 mcg/mL (STE) DIN 02399334 that is
funded under the EAP.
247
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 247, record 148, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Calcitriol Injection USP · DIN 02399334
Manufacturer: Sterimax Inc.; listing date 2016-06-29
Health Canada: Dormant since 2025-04-23 · brand CALCITRIOL INJECTION USP · ATC A11CC04 CALCITRIOL · form Solution · route Intravenous · ingredients CALCITRIOL 1 MCG/ML · company Sterimax inc · schedule Prescription
Calcitriol Injection USP: Formulary list price $9.51 per unit (the source does not state the unit; exact figure $9.5132). What the ministry pays, not the patient.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02399334).
DIN 02399334: Calcitriol Injection USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 881600016; group id 886; item number 2132; lccId None; manufacturer id STE
Source form: Inj Sol Amp-1mL Pk; strength: 1mcg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $9.5132; ministry $9.5132
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02399334
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88422Interchangeable products
Calcijex · DIN 00891738 · not recorded
Shortage status: active shortage (reported June 1, 2024, last updated August 26, 2026) · Tier 3; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399334
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since April 23, 2025 — choose a marketed DIN from the same-category list.
Silkis · DIN 02338572 · 3 mcg/g · Oint
Limited Use, Reason for Use code 191 required; Health Canada lists this DIN as Cancelled post market since 2026-05-31 — choose a marketed DIN from the same-category list.Discontinued May 31, 2026 · checked October 5, 2026
StatusLimited Use, Reason for Use code 191 required; Health Canada lists this DIN as Cancelled post market since 2026-05-31 — choose a marketed DIN from the same-category list.
Write on scriptReason for Use code 191 (criteria below); Health Canada lists this DIN as Cancelled post market since 2026-05-31 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 191
Reason for Use code 191
For the treatment of psoriasis in patients who have failed topical corticosteroids alone, or are intolerant to topical corticosteroids.
Coverage limit:
LU Authorization Period: Indefinite
Exceptional Access criteria on record are for Brand(s): Sterimax Calcitriol Injection; DOSAGE FORM/ STRENGTH: 1 mcg/mL — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Calcitriol
Brand(s): Sterimax Calcitriol Injection
DOSAGE FORM/ STRENGTH: 1 mcg/mL
Case-by-case funding is provided for dialysis patients. Please submit all relevant
clinical data to enable an assessment by the EAP.
Calcitriol Injection, USP (calcitriol) 1mcg/mL Inj Sol – 1mL Pk (imported by STE) –
Effective Date: July 17, 2024
This imported US product (PIN 09858344) is funded under the EAP on a temporary
basis case by case and for those stabilized with an existing EAP approval. This is to
manage a product shortage of calcitriol injection 1 mcg/mL (STE) DIN 02399334 that is
funded under the EAP.
247
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 247, record 148, corpus 2025-01-01; name match only, not an eligibility decision
No interchangeable product listed in the Ontario extract
Silkis · DIN 02338572
Manufacturer: Galderma Canada Inc; listing date 2011-08-04
Health Canada: Cancelled post market since 2026-05-31 · brand SILKIS · ATC D05AX03 CALCITRIOL · form Ointment · route Topical · ingredients CALCITRIOL 3 MCG/G · company Galderma canada inc. · schedule Prescription
DIN 02338572: Silkis
Raw flags: sec12=Y, sec3=Y
Item: 843600090; group id 860; item number 2081; lccId 00212; manufacturer id GAC
Source form: Oint; strength: 3mcg/g
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.3625; ministry $1.3625
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02338572
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82422
Shortage status: discontinued (May 30, 2026, reported by GALDERMA CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02338572
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 31, 2026 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-01-13 — choose a marketed DIN from the same-category list.Discontinued January 13, 2017 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-01-13 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2017-01-13 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Sterimax Calcitriol Injection; DOSAGE FORM/ STRENGTH: 1 mcg/mL — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Calcitriol
Brand(s): Sterimax Calcitriol Injection
DOSAGE FORM/ STRENGTH: 1 mcg/mL
Case-by-case funding is provided for dialysis patients. Please submit all relevant
clinical data to enable an assessment by the EAP.
Calcitriol Injection, USP (calcitriol) 1mcg/mL Inj Sol – 1mL Pk (imported by STE) –
Effective Date: July 17, 2024
This imported US product (PIN 09858344) is funded under the EAP on a temporary
basis case by case and for those stabilized with an existing EAP approval. This is to
manage a product shortage of calcitriol injection 1 mcg/mL (STE) DIN 02399334 that is
funded under the EAP.
247
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 247, record 148, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Calcijex · DIN 00891738
Manufacturer: AbbVie Corporation; listing date 2016-06-29
Health Canada: Cancelled post market since 2017-01-13 · brand CALCIJEX · ATC A11CC04 CALCITRIOL · form Solution · route Intravenous · ingredients CALCITRIOL 1 MCG/ML · company Abbvie corporation · schedule Prescription
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00891738).
DIN 00891738: Calcijex
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 881600016; group id 886; item number 2132; lccId None; manufacturer id ABV
Source form: Inj Sol Amp-1mL Pk; strength: 1mcg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00891738
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11150Interchangeable products
Calcitriol Injection USP · DIN 02399334 · $9.5132
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00891738
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 13, 2017 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (A11CC, D05AX): coverage varies; not interchangeable
Alfacalcidol (One-Alpha): general benefit
Calcipotriol (Dovonex): limited Use 191
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered
Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, FLUOROURACIL, ISOTRETINOIN, ZINC SULFATE
Some products covered without a code (check the product listing): COLLAGENASE
84:36 Miscellaneous Skin and Mucous Membrane Agents
Other drugs in the same formulary class (88:16 Vitamin D) and how they are covered
Matched class: 88:16 Vitamin D
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ALFACALCIDOL
Some products covered without a code (check the product listing): ERGOCALCIFEROL
88:16 Vitamin D
INDICATIONS AND CLINICAL USE
ROCALTROL (calcitriol capsules) is indicated in the management of:
Hypocalcemia and osteodystrophy in patients with chronic renal failure undergoing
dialysis.
Hypocalcemia and its clinical manifestations associated with:
Post-surgical hypoparathyroidism.
Idiopathic hypoparathyroidism.
Pseudohypoparathyroidism.
Vitamin D resistant rickets (familial hypophosphatemia).
Geriatrics (>65 years of age): Limited data are available in patients 65 years of age or older.
Caution should be used when treating elderly patients.
Pediatrics (<18 years of age): The safety and efficacy of calcitriol capsules in children have not
been sufficiently investigated. Use is not recommended in this patient population.
https://pdf.hres.ca/dpd_pm/00059786.PDF
PM date: January 26, 2021
Source product: ROCALTROL; DIN 00481815; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Calcitriol Injection USP · DIN 02399334
Shortage status: active shortage (reported 2024-06-01, last updated 2026-08-26) · Tier 3; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399334
Silkis · DIN 02338572
Shortage status: discontinued (2026-05-30, reported by GALDERMA CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02338572
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Prepare an Exceptional Access request
SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE
Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.
EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026
Posted turnaround and Telephone Request Service scope
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Case-by-case funding is provided for dialysis patients. Please submit all relevant
clinical data to enable an assessment by the EAP.
Calcitriol Injection, USP (calcitriol) 1mcg/mL Inj Sol – 1mL Pk (imported by STE) –
Effective Date: July 17, 2024
This imported US product (PIN 09858344) is funded under the EAP on a temporary
basis case by case and for those stabilized with an existing EAP approval. This is to
manage a product shortage of calcitriol injection 1 mcg/mL (STE) DIN 02399334 that is
funded under the EAP.
247
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.
Other review policies
For Calcitriol Injection USP, Calcijex: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.